B
Beijing Megason Biotechnology
Engineered migrasome technology for targeted drug delivery
About Beijing Megason Biotechnology
Beijing Megason Biotechnology is a company at the forefront of harnessing migrasome biology for therapeutic applications. The company’s core technology revolves around migrasomes, which are large vesicular organelles discovered by Professor Li Yu's research group at Tsinghua University in 2014. These structures are formed during cell migration and play a crucial role in cell-to-cell communication by carrying and releasing signaling molecules like chemokines and cytokines to specific locations.
The company, also known as Migrasome Therapeutics Ltd., is leveraging the natural properties of migrasomes to develop an engineered drug delivery platform. This platform technology aims to overcome challenges faced by current biological delivery systems by offering a method with potentially high biocompatibility, low toxicity, and significant capacity for various drug types. The technology is designed for high modifiability, allowing both internal and external components of the migrasomes to be altered to carry different therapeutic agents. This adaptability is a key feature, enabling the potential for targeted, safe, and efficient delivery of multiple drugs to treat a range of diseases.
The scientific foundation of the company is built upon the extensive research of Professor Li Yu, who first identified these organelles and the process of their formation, termed migracytosis. Migrasomes function as natural packets of information, integrating spatial and temporal signals essential for processes like embryonic development and immune responses. Beijing Megason Biotechnology seeks to translate this fundamental biological discovery into innovative drug delivery systems and novel methods for disease diagnosis and treatment. The company's business model appears to be centered on the research and development of its proprietary migrasome-based platform, with a focus on addressing unmet medical needs through partnerships and the development of its own therapeutic pipeline.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 13.7/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jul 2023 | $14M | $55M | Zhongguancun Development Group · Shoudu Keji Fazhan Jituan · Zhongguancun Collaborative Innovation Fund · Tsinghua Capital | ↗ |
Growth signals
Latest recorded traffic for Beijing Megason Biotechnology is 570 monthly website visits, up 18.8% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Megason Biotechnology in its local ecosystem
The Beijing Megason Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Zhongguancun Development Group- SJShoudu Keji Fazhan Jituan
- ZFZhongguancun Collaborative Innovation Fund
- TCTsinghua Capital
- QTQingjiu Technology
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Megason Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Megason Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.